February 18, 2022
Hosted by Taft Stettinius & Hollister LLP
211 N. Pennsylvania St. Indianapolis, IN 46204
Now that the new administration has been in place almost a year, the outlines of its policies for healthcare and the life sciences industry are beginning to emerge. New leaders at CMS and the FDA are beginning to make their influence felt at their respective organizations. Speakers and panelists will “connect the dots” as to changes in areas like the approach to new product approvals, drug pricing and importation, off-label usage and healthcare coverage and reimbursement.